Acadia Pharmaceuticals Launches Daybue Stix for Rett Syndrome Treatment
Acadia Pharmaceuticals announced Daybue Stix is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and older. The new formulation, approved by the U.S. Food and Drug Administration, FDA, in December 2025, is bioequivalent to the original DAYBUE oral solution, delivering the same efficacy and safety profile, while offering children and adults living with Rett syndrome new flexibility and choice regarding the dose volume and taste of their DAYBUE treatment.
